Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 513-525

  Manderson, Emily N ^a   Birch, Ashley H ^a   Shen, Zhen ^b   Mes Masson, Anne Marie ^b,c   Provencher, Diane ^c,d   Tonin, Patricia N ^b,e,f  

^a Department of Human Genetics ^*  (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Division of Gynecologic Oncology   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

CHL1; Chromosome 3; Ovarian cancer; Tumor suppressor genes

Indexed keywords

CELL ADHESION MOLECULE; COMPLEMENTARY DNA; CONTACTIN 4; CONTACTIN 6; MICROSATELLITE DNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 3P; CONTACTIN 6 GENE; CONTACTTIN 4 GENE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 3; DNA, NEOPLASM; EXONS; FEMALE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEURAL CELL ADHESION MOLECULE L1; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 67651049047     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a3cd38     Document Type: Article

References (75)

1. Bernardini M, Weberpals J, Squire JA. The use of cytogenetics in understanding ovarian cancer. Biomed Pharmacother. 2004;58:17-23.
2. Mertens F, Johansson B, Hoglund M, et al. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 1997;57:2765-2780.
3. Mitelman FJB, Mertens F, eds. Mitelman Database of Chromosome Aberrations in Cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/ Mitelman. 2007. Accessed June 3, 2007.
4. Pejovic T, Heim S, Mandahl N, et al. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer. 1992;4: 58-68.
5. Whang-Peng J, Knutsen T, Douglass EC, et al. Cytogenetic studies in ovarian cancer. Cancer Genet Cytogenet. 1984;11:91-106.
6. Yonescu R, Currie JL, Hedrick L, et al. Chromosome abnormalities in primary endometrioid ovarian carcinoma. Cancer Genet Cytogenet. 1996;87:167-171.
7. Kiechle M, Jacobsen A, Schwarz-Boeger U, et al. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer. 2001;91: 534-540.
8. Staebler A, Heselmeyer-Haddad K, Bell K, et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol. 2002;33:47-59.
9. Taetle R, Aickin M, Yang JM, et al. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer. 1999;25:290-300.
10. Hoglund M, Gisselsson D, Mandahl N, et al. Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution. Genes Chromosomes Cancer. 2001;31:156-171.
11. Simon R, Desper R, Papadimitriou CH, et al. Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis. Genes Chromosomes Cancer. 2000;28:106-120.
12. Taetle R, Aickin M, Panda L, et al. Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes Chromosomes Cancer. 1999;25:46-52.
13. Dodson MK, Hartmann LC, Cliby WA, et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res. 1993;53:4456-4460.
14. Ehlen T, Dubeau L. Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene. 1990;5: 219-223.
15. Fullwood P, Marchini S, Rader JS, et al. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res. 1999;59:4662-4667.
16. Lounis H, Mes-Masson AM, Dion F, et al. Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene. 1998;17: 2359-2365.
17. Petursdottir TE, Thorsteinsdottir U, Jonasson JG, et al. Interstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissues. Genes Chromosomes Cancer. 2004;41:232-242.
18. Zheng JP, Robinson WR, Ehlen T, et al. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res. 1991;51:4045-4051.
19. Rimessi P, Gualandi F, Morelli C, et al. Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene. 1994;9:3467-3474.
20. Cody NA, Ouellet V, Manderson EN, et al. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene. 2007;26:618-632.
21. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSFIA from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20:1509-1518.
22. Imura M, Yamashita S, Cai LY, et al. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines. Cancer Lett. 2006;241:213-220.
23. Kwong J, Lee JY, Wong KK, et al. Candidate tumor-suppressor gene DLECI is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 2006;8:268-278.
24. Tse C, Xiang RH, Bracht T, et al. Human semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res. 2002;62:542-546.
25. Xiang R, Davalos AR, Hensel CH, et al. Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Res. 2002;62:2637-2643.
26. Dallol A, Forgacs E, Martinez A, et al. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTTI (ROBO1) in human cancers. Oncogene. 2002;21: 3020-3028.
27. Huebner K. Tumor suppressors on 3p: a neoclassic quartet. Proc Natl Acad Sci U S A. 2001;98:14763-14765.
28. Imreh S, Klein G, Zabarovsky ER. Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer. 2003;38: 307-321.
29. Xian J, Clark KJ, Fordham R, et al. Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene. Proc Natl Acad Sci U S A. 2001;98: 15062-15066.
30. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 2002;21:6915-6935.
31. Manderson EN, Mes-Masson AM, Novak J, et al. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res. 2002;12:112-121.
32. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest. 1990;63: 132-136.
33. Lounis H, Provencher D, Godbout C, et al. Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res. 1994;215:303-309.
34. Provencher DM, Lounis H, Champoux L, et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim. 2000;36:357-361.
35. Presneau N, Mes-Masson AM, Ge B, et al. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene. 2003;22:1568-1579.
36. Karolchik D, Baertsch R, Diekhans M, et al. The UCSC Genome Browser Database. Nucleic Acids Res. 2003;31:51-54.
37. UniSTS: Integrating Markers and Maps. www.ncbi.nlm.nih.gov/sites/enterz? db=unists. Accessed March 31, 2009.
38. Birch AH, Quinn MC, Filali-Mouhim A, et al. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog. 2008;47:56-65.
39. Presneau N, Dewar K, Forgetta V, et al. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog. 2005;43: 141-154.
40. Ouellet V, Provencher DM, Maugard CM, et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene. 2005;24:4672-4687.
41. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-386.
42. Benson DA, Karsch-Mizrachi I, Lipman DJ, et al. GenBank. Nucl Acids Res. 2007;35:D21-D25. Available at: http://www.ncbi.nlm.nih.gov/Genbank.
43. Arcand SL, Maugard CM, Ghadirian P, et al. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat. 2007;108:399-408.
44. Genome Quebec's Science and Technology Platforms. Available at: http://www.genomequebecplatforms.com. Accessed January 8, 2007.
45. dbSNP Home Page. Available at: www.ncbi.nlm.nih.gov/SNP. 46. Canadian Cancer Society (CCS). Canadian Cancer Statistics 2007. Toronto, Canada: Canadian Cancer Society; 2007.
46. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18 (Suppl 2): S19-S32.
47. Benoit MH, Hudson TJ, Maire G, et al. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol. 2007;30:5-17.
48. Le Page C, Ouellet V, Madore J, et al. Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer. 2006;94:436-445.
49. Tonin PN, Hudson TJ, Rodier F, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001;20:6617-6626.
50. Wojnarowicz PM, Breznan A, Arcand SL, et al. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer. 2008;18:963-975.
51. Dijkhuizen T, van Essen T, van der Vlies P, et al. FISH and array-CGH analysis of a complex chromosome 3 aberration suggests that loss of CNTN4 and CRBN contributes to mental retardation in 3pter deletions. Am J Med Genet A. 2006;140:2482-2487.
52. Fernandez T, Morgan T, Davis N, et al. Disruption of contactin 4 (CNTN4) results in developmental delay and other features of 3p deletion syndrome. Am J Hum Genet. 2004;74:1286-1293.
53. Frints SG, Marynen P, Hartmann D, et al. CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. Hum Mol Genet. 2003;12:1463-1474.
54. Rivera H, Dominguez MG, Matute E. Follow-up of an intelligent odd-mannered teenager with del (3) (p26). Remarks on authorship and ethical commitment. Genet Couns. 2006;17:401-405.
55. Yoshihara Y, Kawasaki M, Tamada A, et al. Overlapping and differential expression of BIG-2, BIG-1, TAG-1, and F3: four members of an axon-associated cell adhesion molecule subgroup of the immunoglobulin superfamily. J Neurobiol. 1995;28:51-69.
56. Zeng L, Zhang C, Xu J, et al. A novel splice variant of the cell adhesion molecule contactin 4 (CNTN4) is mainly expressed in human brain. J Hum Genet. 2002;47:497-499.
57. Miura S, Shibata H, Furuya H, et al. The contactin 4 gene locus at 3p26 is a candidate gene of SCA16. Neurology. 2006;67:1236-1241.
58. Lalonde R, Strazielle C. Brain regions and genes affecting postural control. Prog Neurobiol. 2007;81:45-60.
59. Takeda Y, Akasaka K, Lee S, et al. Impaired motor coordination in mice lacking neural recognition molecule NB-3 of the contactin/F3 subgroup. J Neurobiol. 2003;56:252-265.
60. Cui XY, Hu QD, Tekaya M, et al. NB-3/Notch1 pathway via Deltex1 promotes neural progenitor cell differentiation into oligodendrocytes. J Biol Chem. 2004;279:25858-25865.
61. Yamashita S, Wakazono K, Nomoto T, et al. Expression quantitative trait loci analysis of 13 genes in the rat prostate. Genetics. 2005;171: 1231-1238.
62. Rokman A, Baffoe-Bonnie AB, Gillanders E, et al. Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. Hum Genet. 2005;116:43-50.
63. Wei MH, Karavanova I, Ivanov SV, et al. In silico-initiated cloning and molecular characterization of a novel human member of the L1 gene family of neural cell adhesion molecules. Hum Genet. 1998;103: 355-364.
64. Jakovcevski I, Wu J, Karl N, et al. Glial scar expression of CHL1, the close homolog of the adhesion molecule L1, limits recovery after spinal cord injury. J Neurosci. 2007;27:7222-7233.
65. Montag-Sallaz M, Baarke A, Montag D. Aberrant neuronal connectivity in CHL1-deficient mice is associated with altered information processing-related immediate early gene expression. J Neurobiol. 2003;57:67-80.
66. Morellini F, Lepsveridze E, Kahler B, et al. Reduced reactivity to novelty, impaired social behavior, and enhanced basal synaptic excitatory activity in perforant path projections to the dentate gyrus in young adult mice deficient in the neural cell adhesion molecule CHL1. Mol Cell Neurosci. 2007;34:121-136.
67. Tschentscher F, Husing J, Holter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63:2578-2584.
68. Gimelbrant A, Hutchinson JN, Thompson BR, et al. Widespread monoallelic expression on human autosomes. Science. 2007; 318:1136-1140.
69. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-274.
70. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108-1113.
71. Hoglund M, Gisselsson D, Hansen GB, et al. Ovarian carcinoma develops through multiple modes of chromosomal evolution. Cancer Res. 2003;63:3378-3385.
72. Pathak S, Multani AS. Aneuploidy, stem cells and cancer. EXS. 2006;96:49-64.
73. Vukovic B, Beheshti B, Park P, et al. Correlating breakage-fusion-bridge events with the overall chromosomal instability and in vitro karyotype evolution in prostate cancer. Cytogenet Genome Res. 2007;116:1-11.
74. Bayani J, Brenton JD, Macgregor PF, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res. 2002; 62:3466-3476.
75. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003;362:869-875.